Sanofi's Dupixent To Keep Soaring Despite NICE Blip
HTA Body Rejects Blockbuster For Severe Asthma
Executive Summary
NICE is not recommending Dupixent for severe asthma just yet but Sanofi remains confident of hitting its sales target of €10bn a year.
You may also be interested in...
Real-World Evidence: Sanofi Push Driven By Aetion Deal
Sanofi and US start-up Aetion are to collaborate on integrating their real-world evidence and analytics platforms to improve the clinical development process.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.